In this episode, we explore amycretin, Novo Nordisk's oral dual agonist that targets both GLP-1 and amylin receptors in a single molecule. We break down how it differs from injectable options like CagriSema, review the impressive early trial data showing thirteen percent weight loss in just twelve weeks, discuss why an effective oral option matters for patient access, and look at where it fits in the evolving pipeline of diabetes and obesity medications. Follow us on social media for updates and more content.